| **S2 Table. Response rates (95% CIs) and geometric mean (GM) magnitudes (95% CIs) overall and among positive responders of antibody responses by unadjusted and adjusted statistical methods.** The unadjusted estimates are based on empirical estimates from each study with two-sided 95% CIs, where these estimates do not account for baseline covariates. The adjusted estimates are based on TMLE, accounting for age, sex and BMI. |
| --- |
| **Endpoint** | **Estimate** | **HVTN 100****ALVAC arm** | **HVTN 111****DNA arms\*** |
| **Unadjusted** **estimate** **(95% CI)** | **Adjusted estimate****(95% CI)** | **Unadjusted estimate** **(95% CI)** | **Adjusted estimate****(95% CI)** |
| **IgG****ZM96.C****gp120** | **Response rate** | 100.0%(98.0%, 100.0%) | 100.0%(98.0%, 100.0%) | 100.0%(92.9%, 100.0%) | 100.0%(92.9%, 100.0%) |
| **GM net MFI****(overall)** | 2685.36(2359.30, 3056.47) | 2669.12(2350.04, 3031.54) | 10712.74(8747.64, 13119.20) | 10474.02(8455.21, 12974.84) |
| **GM net MFI****(among positive responders)** | 2685.36(2359.30, 3056.47) | 2669.12(2350.04, 3031.54) | 10712.74(8747.64, 13119.20) | 10474.02(8455.21, 12974.84) |
| **IgG****1086.C****gp120** | **Response rate** | 100.0%(98.0%, 100.0%) | 100.0%(98.0%, 100.0%) | 100.0%(93.0%, 100.0%) | 100.0%(93.0%, 100.0%) |
| **GM net MFI****(overall)** | 26257.50 (25107.21, 27460.00) | 21613.02(20911.25, 22338.34) | 29973.28 (28904.16, 31081.00) | 22784.80(22455.45, 23118.97) |
| **GM net MFI****(among positive responders)** | 26257.5 (25107.21, 27460.00) | 21613.02(20911.25, 22338.34) | 29973.28 (28904.16, 31081.00) | 22784.80(22455.45, 23118.97) |
| **IgG****TV1c8.2.C** **gp120** | **Response rate** | 100.0%(98.0%, 100.0%) | 100.0%(98.0%, 100.0%) | 100.0%(93.0%, 100.0%) | 100.0%(93.0%, 100.0%) |
| **GM net MFI****(overall)** | 10726.75 (9480.84, 12136.30) | 10255.76(9133.37, 11516.09) | 20332.61 (17692.84, 23366.00) | 17364.90(15232.20, 19796.21) |
| **GM net MFI****(among positive responders)** | 10726.75(9480.84, 12136.30) | 10255.76(9133.37, 11516.09) | 20332.61(17692.84, 23366.00) | 17364.90(15232.20, 19796.21) |
| **IgG** **1086.C** **V1V2** | **Response rate** | 72.8%(66.0%, 78.7%) | 72.7%(66.2%, 79.2%) | 95.6%(85.2%, 98.8%) | 96.6%(91.4%, 100.0%) |
| **GM net MFI (overall)** | 351.23(242.11, 509.54) | 352.19(241.94, 512.68) | 2186.96(1260.82, 3793.42) | 2203.44(1281.92, 3787.39) |
| **GM net MFI (among positive responders)** | 1214.97(981.35, 1504.21) | 1200.93(944.38, 1527.16) | 2725.40(1765.96, 4206.11) | 2833.33(1811.93, 4430.51) |
| **IgG** **TV1c8.2.C** **V1V2** | **Response rate** | 60.8%(53.0%, 68.0%) | 60.4%(52.5%, 68.3%) | 73.3%(59.0%, 84.0%) | 73.5%(59.1%, 88.0%) |
| **GM net MFI (overall)** | 376.92(215.53, 659.17) | 361.82(202.86, 645.35) | 538.74(185.92, 1561.07) | 573.02(192.77, 1703.32) |
| **GM net MFI (among positive responders)** | 3558.92(2708.49, 4676.37) | 3533.31(2670.58, 4674.75) | 3496.19(2058.23, 5938.79) | 2954.41(1657.19, 5267.06) |
| **IgG****CaseA2\_gp70\_****V1V2.B**  | **Response rate** | 55.4%(48.2%, 62.4%) | 55.0%(47.8%, 62.2%) | 60.0%(45.5%, 73.0%) | 58.7%(42.2%, 75.3%) |
| **GM net MFI (overall)** | 80.26(51.23, 125.73) | 79.46(50.56, 124.88) | 184.44(65.24, 521.39) | 211.57(72.77, 615.11) |
| **GM net MFI (among positive responders)** | 728.96(552.36, 962.00) | 744.57(555.75, 997.54) | 2136.18(1291.57, 3533.10) | 2314.04(1196.21, 4476.44) |
| **IgG gp41** | **Response rate** | 0.5%(0.1%, 3.0%) | 0.5%(0.1%, 3.0%) | 2.2%(0.4%, 11.6%) | 2.2%(0.4%, 11.6%) |
| **GM net MFI (overall)** | 178.81(132.52, 241.26) | 175.52(129.60, 237.70) | 485.47(321.65, 732.73) | 466.94(301.79, 722.44) |
| **GM net MFI (among positive responders)** | 6636.25 (NA\*\*) | NA\*\* | 7177.75 (NA\*\*) | NA\*\* |
| **nAb TV1c8.2.C** | **Response rate** | 98.4%(95.3%, 99.5%) | 98.4%(95.3%, 99.5%) | 100.0%(93.2%, 100.0%) | 100.0%(93.2%, 100.0%) |
| **GM ID50 titer (overall)** | 97.34(85.22, 111.19) | 95.67(83.71, 109.35) | 185.65(151.24, 227.89) | 187.45(154.25, 227.79) |
| **GM ID50 titer (among positive responders)** | 102.22(90.40, 115.59) | 100.38(88.68, 113.62) | 185.65(151.24, 227.89) | 187.30(154.12, 227.62) |
| **nAb MW965.26.C** | **Response rate** | 98.9%(96.1%, 99.7%) | 98.9%(96.1%, 99.7%) | 100.0%(93.2%, 100.0%) | 100.0%(93.2%, 100.0%) |
| **GM ID50 titer (overall)** | 259.69(219.05, 307.87) | 255.13(214.63, 303.27) | 574.25(456.60, 722.21) | 575.48(466.65, 709.69) |
| **GM ID50 titer (among positive responders)** | 271.15(230.83, 318.51) | 265.66(225.22, 313.38) | 574.25(456.60, 722.21) | 577.67(469.51, 710.75) |
| \*HVTN 111 DNA arms refer to the pooled needle and Biojector DNA vaccine arms for binding and neutralizing antibody responses\*\*NA: not available as only n=1 positive responder for gp41 |